There are two main groups of IDH1/2 mutant gliomas: (i) astrocytomas exhibiting ATRX mutation, TP53 mutation and ALT activation, (ii) oligodendrogliomas harboring 1p/19q codeletion and hTERT promoter mutation with hTERT overexpression. This evidence concerns the gene GPT and central nervous system cancer.